MARKET

ALLR

ALLR

Allarity
NASDAQ
0.4400
+0.0120
+2.80%
Closed 13:00 11/25 EST
OPEN
0.4800
PREV CLOSE
0.4280
HIGH
0.4800
LOW
0.4100
VOLUME
52.45K
TURNOVER
20.05K
52 WEEK HIGH
18.20
52 WEEK LOW
0.3610
MARKET CAP
4.51M
P/E (TTM)
-0.0960
1D
5D
1M
3M
1Y
5Y
Allarity Therapeutics reports Q3 results
Seekingalpha · 11/15 21:55
Allarity Therapeutics Q3 EPS $(0.68) Down From $(0.17) YoY
Benzinga · 11/15 21:02
Reported Late Monday, Allarity Therapeutics Announces Adjournment Of 2022 Annual Meeting of Stockholders Until December 2, 2022
Benzinga · 11/08 05:16
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Benzinga · 11/07 08:07
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Benzinga · 11/03 09:40
Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform
By Rachael Green, Benzinga
News Direct · 10/18 12:00
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares increased by 10.8% to $0.39 during Monday's after-market session. The market value of their outstanding shares is at $16.8 million.
Benzinga · 10/17 21:51
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Gainers Agrify Corporation (NASDAQ: AGFY) climbed 53.8% to close at $1.45. FedNat Holding Company (NASDAQ: FNHC) gained 48% to settle at $0.52.
Benzinga · 10/17 09:21
More
About ALLR
Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Webull offers kinds of Allarity Therapeutics Inc stock information, including NASDAQ:ALLR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALLR stock methods without spending real money on the virtual paper trading platform.